PSMA PET in Active Surveillance: Initial Experiences and Future Directions
Open Access
Abstract
Background/Objectives: We conducted an exploratory review of patients in our institutions who had undergone a PSMA PET/CT whilst on active surveillance, determining patient characteristics and trends. Methods: A retrospective cohort study of patients who were on active surveillance for low or favourable intermediate-risk prostate cancer and had a PSMA PET/CT done due to the presence of risk factors was performed. Risk factors that were an indication for PSMA PET/CT were: The presence of ISUP GG 2 disease, or ISUP GG1 disease with a PSA > 10 or a PI-RADS score of 4 or 5 on their MRI. Results: We identified 45 patients who underwent PSMA PET/CT whilst on active surveillance. Of these patients, 14 remained on active surveillance at the time of review, whilst 31 had progressed to definitive treatment. There was a significantly different distribution of PRIMARY scores between these two groups, although the average SUVMax was similar. In our practice, we found PSMA PET/CT to be particularly useful when performing confirmatory biopsies on patients who had normal MRI scans or were unable to go for the MRI at the time of diagnosis. Conclusions: PSMA PET/CT shows promise as a tool for active surveillance, particularly in men with risk factors for progressing to active treatment. However, our cohort was too small to draw definitive conclusions, and further research is needed.Keywords
Funding Information
- the Commonwealth through an Australian Government Research Training Program Scholarship
This publication has 28 references indexed in Scilit:
- [68Ga]Ga-PSMA PET/CT in active surveillance: From imaging to informed decision-making — a “Whistling Arrow” perspectiveEuropean Journal of Nuclear Medicine and Molecular Imaging, 2026
- Istanbul PSMA PET/CT criteria (IPPC): an imaging-based approach to patient selection for active surveillanceEuropean Journal of Nuclear Medicine and Molecular Imaging, 2025
- Early Results from the CONFIRM Trial: Utility of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate CancerEuropean Urology Oncology, 2025
- Imaging in Diagnosis and Active Surveillance for Prostate CancerJAMA Surgery, 2025
- Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical RegistryEuropean Urology Oncology, 2024
- Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate Cancer Trial (PASPoRT)European Urology Oncology, 2023
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0European Journal of Nuclear Medicine and Molecular Imaging, 2023
- Prospective Longitudinal Health-related Quality of Life Analysis of the Finnish Arm of the PRIAS Active Surveillance Cohort: 11 Years of Follow-upEuropean Urology Focus, 2022
- Active Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and MetaregressionEuropean Urology Oncology, 2022
- Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancerCochrane Database of Systematic Reviews, 2019